Left atrial appendage closure (LAAC) in non-valvular atrial fibrillation with high risk of bleeding has shown promising results with first generation devices (with the Watchman) in the different studies. At present, we have a more modern device, the Watchman FLX, but we do not have much information about it. To gather more data, researchers looked<a href="https://solaci.org/en/2022/08/18/left-atrial-appendage-closure-is-safe-with-the-new-devices/" title="Read more" >...</a>
The incidence of left ventricular thrombosis (LVT) after anterior ST-segment elevation myocardial infarction (STEMI) ranges from 4% to 26%. This is associated with bad long-term evolution. In the past, triple-scheme therapy (vitamin K antagonist plus dual antiplatelet therapy) was recommended to prevent LVT, despite the lack of high-quality scientific evidence and an increase in the<a href="https://solaci.org/en/2022/05/05/prophylactic-rivaroxaban-therapy-for-left-ventricular-thrombus-after-st-segment-elevation-acute-coronary-syndrome/" title="Read more" >...</a>
Much has been published recently on short term dual antiplatelet therapy (DAPT) both in acute (ACS) and chronic coronary syndrome (CCS) as well as safety of P2Y12 inhibitor monotherapy. When discussing secondary prevention in patients with established coronary artery disease, aspirin (ASA) has been the preferred drug for the prevention of new atherothrombotic events. This<a href="https://solaci.org/en/2022/04/27/should-aspirin-be-the-standard-of-secondary-prevention-of-mace/" title="Read more" >...</a>
Left atrial appendage occlusion (LAAO) is an alternative to prevent atrial fibrillation stroke mainly used in patients at high risk for bleeding. One of the most widely used devices in randomized trials is the Watchman, which yielded promising results. However, its real-life performance had yet to be analyzed. Researchers conducted an analysis of the National<a href="https://solaci.org/en/2022/04/25/should-we-use-left-atrial-appendage-occlusion-more-frequently-what-real-life-data-are-available/" title="Read more" >...</a>
The WOEST study found a significant reduction in bleeding complications post PCI with oral anticoagulation indication (OAC) when treating patients with dual antiplatelet therapy (DAPT) vs. the triple antithrombotic scheme. Several randomized studies have shown these results. At present, the guidelines recommend using the triple antithrombotic scheme in patients according to ischemic and bleeding risk. <a href="https://solaci.org/en/2022/04/22/woest-2-dual-versus-triple-antithrombotic-scheme-in-the-real-world-antiplatelet-therapy-anticoagulation-scheme/" title="Read more" >...</a>
This study was presented in phase 2, in a healthy population between 50 and 80 years of age, and it showed the use of Bentracimab reverts the antiplatelet effect of ticagrelor. The study included 205 adults mean age 61, 49% women, previously treated with aspirin and ticagrelor for 48 hrs. who were randomized 3:1 to<a href="https://solaci.org/en/2022/04/11/acc-2022-bentracimab/" title="Read more" >...</a>
Difficult to treat, tricuspid valve failure poses great medical challenge. In addition, the mortality rate of surgical treatment these days is not exactly low, involving high risk, which often takes this alternative off the table. Several percutaneous devices have been developed to treat this disease, the most popular being edge-to-edge devices. The TRICENTO has an<a href="https://solaci.org/en/2022/03/25/tricento-promising-results-for-severe-tricuspid-valve-regurgitation/" title="Read more" >...</a>
The benefit of first-generation Drug-Eluting Stents (DES) over Bare Metal Stents (BMS) is largely known. Moreover, technological developments have led to reduced strut size, biodegradable polymers, and new scaffolds, which in turn have led to improved outcomes. These are known as ultrathin stents, and its struts measure between 70 and 100 microns, which contributes to<a href="https://solaci.org/en/2022/03/23/drug-eluting-stents-does-strut-size-matter/" title="Read more" >...</a>
Coronary artery disease is the main cause of death in patients with functioning renal transplant, reaching 30%, with the highest rate at peri transplant stage. At the same time, the incidence of acute myocardial infraction (AMI) after renal transplant ranges from 5% to 11%. This is why asymptomatic candidates are routinely screened for CAD before<a href="https://solaci.org/en/2022/03/22/is-coronary-revascularization-useful-in-renal-transplant-candidates/" title="Read more" >...</a>
Compared with patients with chronic coronary syndromes, patients with acute coronary syndromes (ACS) are more likely to suffer from long term major adverse cardiac events (MACE). To prevent this, both the American and the European guidelines recommend prolonging dual antiplatelet therapy (DAPT) in this population for at least 12 months. However, in patients with certain clinical<a href="https://solaci.org/en/2022/03/21/abbreviated-dapt-in-acs-the-end-of-clopidogrel-monotherapy/" title="Read more" >...</a>